Entries by Thomas Gabrielczyk

Evotec receives CARB-X funding

Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8,4m funding from CARB-X for co-development of a first-in-class antibiotic.

AMR: Big Pharma sets up US$1bn Fund

After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).